Daru. 2026 Jun 10;34(2):33. doi: 10.1007/s40199-026-00609-x.
ABSTRACT
BACKGROUND: Growing evidence supports the therapeutic role of nutraceuticals as complementary and alternative therapies in patients with type 2 diabetes mellitus (T2DM). Resveratrol, a natural polyphenol compound has been shown to modulate metabolically disturbances include insulin resistance and lipid profile disturbances.
OBJECTIVES: This umbrella review and meta-analysis study conducted to assess the effect of resveratrol on glycemic indices and lipid profile in T2DM.
METHODS: The study was performed by using the Preferred Reporting Items for Systematic Review and Meta-Analyses guidelines (PRISMA) checklist. The PubMed, Web of Sciences, and Google Scholar databases were used to search the published papers up to 2025. The AMSTAR questionnaire was used for assessing the quality of eligible studies. Additionally, The Cochran Q test and I2 statistics were used for examining heterogeneity.
RESULTS: Of 10 meta-analyses evaluating the resveratrol effects on glycemic indices and lipid profile showed no significant effects on fasting blood sugar, glycosylated hemoglobin A1c (HbA1c), insulin, homeostatic model assessment for insulin resistance (HOMA-IR), low-density lipoprotein-cholesterol (LDL-C), high-density lipoprotein-cholesterol (HDL-C), triglyceride (TG), total cholesterol (TC), despite significant heterogeneity. Nevertheless, based on SMD analyses, resveratrol supplementation showed only significant effects on LDL-C reduction. Also, significant decline in serum insulin level was observed for sample size ≥ 500 and study number ≥ 10.
CONCLUSION: Given the high heterogeneity and limitations attributed to the study, resveratrol supplementation was not considered as a beneficial agent in declining glycemic indices and lipid profile in patients with T2DM.
PMID:42268476 | DOI:10.1007/s40199-026-00609-x
